UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
PRINCETON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
URGN - UroGen Pharma Ltd.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$44.75
DETAILS
HIGH:
$50.00
LOW:
$40.00
MEDIAN:
$44.50
CONSENSUS:
$44.75
UPSIDE:
11.88%
Stock News
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
According to this Form 4 filing, the CMO of UroGen Pharma sold 10,000 shares at $40.00 per share, totaling $400,000 in transaction proceeds. The sale represented 8% of the insider's direct equity holdings in the company, as reported in the Form 4.
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumor immune activation PRINCETON, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?
Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?
10,000 shares were sold for a transaction value of ~$350,000 at a weighted average price of around $35.01 per share on June 22, 2026. The sale represented 7.15% of Mark Schoenberg's direct holdings, reducing his position from 139,763 to 129,763 shares of common stock.
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?
5,222 shares were sold on June 8, 2026 for a transaction value of approximately $143,000 at a weighted average price around $27.30 per share. The transaction represented 3.60% of Mark Schoenberg's direct holdings, reducing his position from 144,985 to 139,763 shares.
UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
Agreement reinforces the value of UroGen's innovation and reflects the strength of the Company's intellectual property portfolio Teva will be granted a non-exclusive license to sell its generic version of JELMYTO beginning on September 15, 2030, if approved by the FDA PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference to take place on June 8-10, 2026.
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
PRINCETON, N. J. , June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference to take place on June 8-10, 2026.
UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript
UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three Months First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, Urogen Pharma (URGN) is looking like an interesting pick, as it just reached a key level of support. URGN's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027
UroGen Pharma is reaffirmed as a Strong Buy, with a 12-month price target raised to $39/share, reflecting robust Q1 2026 results. Zusduri sales more than doubled QoQ to $29.2M, driven by the January J-code assignment, validating the trajectory toward profitability by 2027. URGN's path to profitability is underpinned by >91% gross margins, disciplined expense control, and a realistic break-even threshold of $305M annual revenue.
UroGen Pharma to Present at Upcoming Investor Conferences
PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript
UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.92 per share a year ago.
Price Targets
UroGen Pharma (URGN) PT Raised to $50 at Oppenheimer
$50.00
(was $39.80)
Leland Gershell
·
Oppenheimer
UroGen Pharma price target raised to $44 from $18 at Goldman Sachs
$44.00
(was $39.80)
Goldman Sachs
UroGen Pharma price target raised to $45 from $40 at H.C. Wainwright
$45.00
(was $29.40)
Raghuram Selvaraju
·
H.C. Wainwright
UroGen Pharma initiated with a Buy at Jefferies
$40.00
(was $20.53)
Amin Makarem
·
Jefferies
UroGen Pharma price target raised to $16 from $3 at Goldman Sachs
$16.00
(was $12.03)
Paul Choi
·
Goldman Sachs
UroGen Pharma price target raised to $31 from $10 at Oppenheimer
$31.00
(was $12.03)
Leland Gershell
·
Oppenheimer
EF Hutton Starts UroGen Pharma (URGN) at Buy
$25.00
(was $12.60)
Jason Kolbert
·
EF Hutton
Hasbro To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday
$46.00
(was $20.26)
Stephen Richardson
·
Evercore ISI
UroGen Pharma price target raised to $40 from $32 at Oppenheimer
$40.00
(was $17.50)
Leland Gershell
·
Oppenheimer
UroGen Pharma price target raised to $60 from $54 at H.C. Wainwright
$60.00
(was $17.50)
Raghuram Selvaraju
·
H.C. Wainwright
Goldman Sachs Reiterates Neutral Rating on UroGen Pharma (URGN)
$22.00
(was $17.50)
Paul Choi
·
Goldman Sachs
UroGen Pharma (URGN) PT Lowered to $32 at Oppenheimer
$32.00
(was $13.07)
Leland Gershell
·
Oppenheimer
UroGen Pharma (URGN) PT Lowered to $34 at Oppenheimer
$34.00
(was $14.46)
Leland Gershell
·
Oppenheimer
HC Wainwright & Co. Maintains Buy on UroGen Pharma, Lowers Price Target to $23
$23.00
(was $7.94)
H.C. Wainwright